SQUINTO STEPHEN P

SEC source: 0001104659-22-063509 · tm2216253-5_4seq1.xml · derivative · entry 3

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,318

Underlying: Common Stock · 15,318 shares

Expires 2032-05-19

F3 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.

F4 · derivative.exercise_date: The options shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.

SEC source: 0001104659-22-063509 · tm2216253-5_4seq1.xml · nonDerivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,652

F1 · kind: This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.

SEC source: 0000899243-22-007423 · doc4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-02-17

F1 · derivative.exercise_date: This option vests in substantially equal monthly installments over four years.

SEC source: 0001104659-21-070514 · tm2117215-1_4seq1.xml · derivative · entry 3

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,998

Underlying: Common Stock · 6,998 shares

Expires 2031-05-20

F3 · derivative.exercise_date: The options shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.

SEC source: 0001104659-21-070514 · tm2117215-1_4seq1.xml · nonDerivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,834

F1 · shares: Represents restricted stock awards. The restricted stock awards shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.

SEC source: 0001104659-21-056732 · tm2114187d3_4.xml · nonDerivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,728

F1 · kind: The sale transaction reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.00 to $77.72, inclusive.

F3 · balance_after: Includes shares of common stock held by a trust (i) the beneficiaries of which are the Reporting Person's children and (ii) of which the Reporting Person is the trustee.

SEC source: 0001104659-21-056732 · tm2114187d3_4.xml · nonDerivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,959

F1 · kind: The sale transaction reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.00 to $75.10, inclusive.

F3 · balance_after: Includes shares of common stock held by a trust (i) the beneficiaries of which are the Reporting Person's children and (ii) of which the Reporting Person is the trustee.

SEC source: 0001104659-21-053237 · tm2113689d6_4.xml · derivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,768

Underlying: American Depositary Shares · 23,768 shares

Expires 2031-04-19

F3 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.

F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.

SEC source: 0001104659-21-051578 · tm2113336-1_4seq1.xml · nonDerivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,160

F1 · kind: The sale transaction reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.00 to $75.04, inclusive.

F3 · balance_after: Includes shares of common stock held by a trust (i) the beneficiaries of which are the Reporting Person's children and (ii) of which the Reporting Person is the trustee.

SEC source: 0001104659-21-051578 · tm2113336-1_4seq1.xml · nonDerivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,217

F1 · kind: The sale transaction reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.04 to $75.41, inclusive.

F3 · balance_after: Includes shares of common stock held by a trust (i) the beneficiaries of which are the Reporting Person's children and (ii) of which the Reporting Person is the trustee.

SEC source: 0000899243-20-021971 · doc4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-08-06

F1 · derivative.exercise_date: 50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001104659-20-065411 · tm2020645d5_form4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,464

Underlying: Common Stock · 7,464 shares

Expires 2030-05-20

F1 · derivative.exercise_date: This option shall vest in full on the earlier of (1) May 20, 2021 or (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.

SEC source: 0001104659-20-033095 · tm2012720d1_4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person.

SEC source: 0001209191-20-014671 · doc4.xml · derivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director · Head of Research and Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,836

Underlying: Common Stock · 33,836 shares

Expires 2030-02-27

F2 · derivative.exercise_date: The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

SEC source: 0001209191-20-014671 · doc4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · Head of Research and Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,776

Underlying: Common Stock · 185,776 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.

SEC source: 0001144204-19-045297 · tv529790_form4.xml · derivative · entry 5

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,053,204 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F2 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F2 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-045297 · tv529790_form4.xml · derivative · entry 4

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 6,078,103 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-045297 · tv529790_form4.xml · nonDerivative · entry 3

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,406,307

F3 · ownership.nature: Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-045297 · tv529790_form4.xml · nonDerivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,131,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-045297 · tv529790_form4.xml · nonDerivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,078,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-044792 · tv529540_form4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,983

Underlying: Common Stock · 29,983 shares

Expires 2029-09-12

F1 · derivative.exercise_date: This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date.

SEC source: 0001144204-19-044792 · tv529540_form4.xml · derivative · entry 3

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,053,204

Underlying: Common Stock · 1,053,204 shares

Expires not disclosed

F4 · derivative.exercise_price: On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F4 · price: On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F4 · derivative.exercise_date: On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F4 · derivative.expiration_date: On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by GP VI. GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001144204-19-044792 · tv529540_form4.xml · derivative · entry 2

SQUINTO STEPHEN P · CIK 0001231954 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,078,103

Underlying: Common Stock · 6,078,103 shares

Expires not disclosed

F2 · derivative.exercise_price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F2 · price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F2 · derivative.exercise_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F2 · derivative.expiration_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.

F3 · ownership.nature: Shares held by GP VI. GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-056535 · doc4.xml · derivative · entry 1

SQUINTO STEPHEN P · CIK 0001231954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2027-10-08

F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date.